Dentistry Medical News about CD44v6 levels

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy
Oral Diseases , 07/01/09

Chang SM et al. - In a trial to determine the levels of serum sCD44v6 in pts with oral cancer and evaluate the value of serum sCD44v6 in adjuvant diagnosis, staging, and monitoring treatment response in these pts, it was concluded that the possible roles of CD44v6 in diagnosis of oral and maxillofacial malignancy deserve further elucidation and evaluation. Serum sCD44v6 may be a valuable marker in monitoring treatment response in pts with OSCC.

Methods

112 hospitalized pts with oral and maxillofacial malignancy and 28 healthy individuals were examined for serum sCD44v6 levels.
Venous blood was collected from pts and healthy individuals.
1 wk after treatment, venous blood was collected once again in 60 pts with oral and maxillofacial squamous cell carcinoma (OSCC).

Results

The sCD44v6 concentration was not significantly different between pts with oral and maxillofacial malignancy and control group.
Levels of serum sCD44v6 in pts with OSCC and salivary carcinoma showed no difference with those in control group.
sCD44v6 level in pts with stage III and IV disease was higher than that of pts with stage I and II and that of the control group, but the difference was not significant.
Serum sCD44v6 levels in pts with OSCC after treatment became lower than that prevailed during pretreatment.

<< Previous
The therapeutic use of botulinum toxin in cervical and...

Next >>
Electrocardiographic Alterations During Endosseous Implant...

B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients
Arthritis & Rheumatism, 11/04/09 Relevance Score: 47%

Increased levels of circulating microparticles in primary Sjogrens syndrome, systemic lupus erythematosus and rheumatoid arthritis, and relation with disease activity
Arthritis Research & Therapy, 10/20/09 Relevance Score: 47%

25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus
Arthritis Care and Research, 10/01/09 Relevance Score: 47%

Low folate levels may be an atherogenic factor regardless of homocysteine levels in young healthy nonsmokers
Metabolism-Clinical and Experimental, 11/20/09 Relevance Score: 46%

Segmental Contribution Toward Total Lumbar Range of Motion in Disc Replacement and Fusions: A Comparison of Operative and Adjacent Levels
Spine, 11/02/09 Relevance Score: 46%